In contrast to previous approaches that utilized exogenous antioxidant administration to prevent BPD, the use of therapeutic TXNRD1 inhibition enhances endogenous Nrf2-dependent responses and is associated with improved lung development. This evidence concerns the gene TXNRD1 and bronchopulmonary dysplasia.